Literature DB >> 856901

Partial characterization of in vivo chemotactic activity: comparison to human C5a.

L D Robinson, S K Wooten, M E Miller.   

Abstract

Spontaneous eosinophil chemotactic activity (SECA) can mediate the directed movement of human eosinophils and neutrophils. Preliminary characterization of SECA has been carried out. SECA is nondialyzable and heat-stable (56 degrees C, 30 min). Chromatography on Sephadex G-75 demonstrated that SECA had elutional and functional properties similar to C5a (prepared from endotoxin-activated normal sera). Polyacrylamide gel electrophoresis (PAGE) with the use of 15% bisacrylamide gels of lyophilized, chemotactically active column fractions demonstrated a single protein band of identical electrophoretic mobility from either SECA or C5a preparations. Enzymatic hydrolysis with carboxypeptidase B, a known inhibitor of C5a activity, significantly decreased chemotactic activities of C5a and SECA. The addition of purified anti-C5 to either SECA or C5a significantly inhibited chemotactic activity. SECA is naturally occurring chemotactic activity identical to human C5a. Thus C5a may be an important source of in vivo chemotactic activity in various inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856901     DOI: 10.1016/0091-6749(77)90017-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

1.  Eosinophil granule cationic proteins regulate the classical pathway of complement.

Authors:  J M Weiler; R E Edens; C S Bell; G J Gleich
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

2.  Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.

Authors:  H D Perez; D E Chenoweth; I M Goldstein
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  Eosinopenia of acute infection: Production of eosinopenia by chemotactic factors of acute inflammation.

Authors:  D A Bass; T A Gonwa; P Szejda; M S Cousart; L R DeChatelet; C E McCall
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.